Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New brain scan could spot Alzheimer's earlier

NCT ID NCT07580703

Diagnosis Sponsor: Eli Radiopharma Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a radioactive tracer called [18F]Flortaucipir, used during a PET scan to detect tau protein tangles in the brain—a hallmark of Alzheimer's disease. Researchers will enroll 18 Chinese adults aged 50-85 with normal cognition, mild cognitive impairment, or Alzheimer's to check the tracer's safety, how it moves through the body, and how well it spots disease signs. The goal is to see if this imaging method can help diagnose Alzheimer's more accurately.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
[18F]Flortaucipir Injection (a radioactive tracer for PET scans)
What this could lead to
If successful, this could improve early detection of Alzheimer's disease by showing tau protein buildup in the brain.
What could go wrong
This is a very early Phase I study with only 18 participants, so results may not apply broadly. The tracer involves radiation exposure, and its diagnostic accuracy is still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 18 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed informed consent form (ICF). * Male or female aged 50-85 years. * Education level sufficient to cooperate with neuropsychological testing and obtain reliable results. * Meet the following criteria related to cognitive impairment: 1. CN: No history of cognitive impairment, Aβ-PET negative, MRI without clinically significant neurodegenerative changes. 2. MCI: Meet core criteria for AD-related MCI, Aβ-PET positive, MRI showing neurodegenerative changes. 3. AD: Meet core criteria for probable AD dementia, Aβ-PET positive, MRI showing neurodegenerative changes. * Fertile individuals: No plan for reproduction, sperm/egg donation within 6 months after signing ICF and until 6 months after study drug administration; and agreement to use highly effective contraception (including partner). Exclusion Criteria: * Pregnant (positive pregnancy test at screening or before administration) or breastfeeding women. * Major surgery within 1 month prior to screening, or planned surgery during the study period. * Known allergy to radioactive radiation, alcohol, \[18F\]Flortaucipir injection, or its excipients, or other severe allergic reactions. * Cognitive impairment due to causes other than AD. * Clinically significant infarction or probable multi-infarct dementia. * Current clinically significant psychiatric illness (e.g., major depression, schizophrenia). * History of epilepsy or seizures (except febrile seizures in childhood). * Inability to tolerate PET/MRI or presence of contraindications to PET/MRI. * Other neurodegenerative diseases or dementias other than AD dementia. * Any other condition that, in the investigator's opinion, makes the subject unsuitable for the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ad - Alzheimer's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ad - Alzheimer's disease MCI

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chinese PLA General Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100853, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.